cloudfront

Report Detail

Pharma & HealthcareGlobal Tardive Dyskinesia (TD) Therapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • RnM2541250
  • |
  • 06 November, 2018
  • |
  • Global
  • |
  • 118 pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

Global Tardive Dyskinesia (TD) Therapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Table of Contents

    1 Market Overview

    • 1.1 Tardive Dyskinesia (TD) Therapy Introduction
    • 1.2 Market Analysis by Type
    • 1.2.1 Valbenazine
  • 1.2.2 Amantadine
  • 1.2.3 Tetrabenazine
  • 1.2.4 Clonazepam
  • 1.2.5 Others
  • 1.3 Market Analysis by Applications
  • 1.3.1 Hospitals
  • 1.3.2 Clinics
  • 1.3.3 Others
  • 1.4 Market Analysis by Regions
  • 1.4.1 North America (United States, Canada and Mexico)
  • 1.4.1.1 United States Market States and Outlook (2013-2023)
  • 1.4.1.2 Canada Market States and Outlook (2013-2023)
  • 1.4.1.3 Mexico Market States and Outlook (2013-2023)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
  • 1.4.2.1 Germany Market States and Outlook (2013-2023)
  • 1.4.2.2 France Market States and Outlook (2013-2023)
  • 1.4.2.3 UK Market States and Outlook (2013-2023)
  • 1.4.2.4 Russia Market States and Outlook (2013-2023)
  • 1.4.2.5 Italy Market States and Outlook (2013-2023)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • 1.4.3.1 China Market States and Outlook (2013-2023)
  • 1.4.3.2 Japan Market States and Outlook (2013-2023)
  • 1.4.3.3 Korea Market States and Outlook (2013-2023)
  • 1.4.3.4 India Market States and Outlook (2013-2023)
  • 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
  • 1.4.4 South America, Middle East and Africa
  • 1.4.4.1 Brazil Market States and Outlook (2013-2023)
  • 1.4.4.2 Egypt Market States and Outlook (2013-2023)
  • 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
  • 1.4.4.4 South Africa Market States and Outlook (2013-2023)
  • 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
  • 1.5 Market Dynamics
  • 1.5.1 Market Opportunities
  • 1.5.2 Market Risk
  • 1.5.3 Market Driving Force
  • 2 Manufacturers Profiles

    • 2.1 Teva Pharma
    • 2.1.1 Business Overview
  • 2.1.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.1.2.1 Product A
  • 2.1.2.2 Product B
  • 2.1.3 Teva Pharma Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.2 Biogen
  • 2.2.1 Business Overview
  • 2.2.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.2.2.1 Product A
  • 2.2.2.2 Product B
  • 2.2.3 Biogen Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.3 Johnson & Johnson
  • 2.3.1 Business Overview
  • 2.3.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.3.2.1 Product A
  • 2.3.2.2 Product B
  • 2.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.4 GlaxoSmithKline
  • 2.4.1 Business Overview
  • 2.4.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.4.2.1 Product A
  • 2.4.2.2 Product B
  • 2.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.5 Neurocrine Biosciences
  • 2.5.1 Business Overview
  • 2.5.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.5.2.1 Product A
  • 2.5.2.2 Product B
  • 2.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.6 Pfizer
  • 2.6.1 Business Overview
  • 2.6.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.6.2.1 Product A
  • 2.6.2.2 Product B
  • 2.6.3 Pfizer Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.7 Novartis
  • 2.7.1 Business Overview
  • 2.7.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.7.2.1 Product A
  • 2.7.2.2 Product B
  • 2.7.3 Novartis Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.8 Sanofi
  • 2.8.1 Business Overview
  • 2.8.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.8.2.1 Product A
  • 2.8.2.2 Product B
  • 2.8.3 Sanofi Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.9 AstraZeneca
  • 2.9.1 Business Overview
  • 2.9.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.9.2.1 Product A
  • 2.9.2.2 Product B
  • 2.9.3 AstraZeneca Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.10 Bayer AG
  • 2.10.1 Business Overview
  • 2.10.2 Tardive Dyskinesia (TD) Therapy Type and Applications
  • 2.10.2.1 Product A
  • 2.10.2.2 Product B
  • 2.10.3 Bayer AG Tardive Dyskinesia (TD) Therapy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 3 Global Tardive Dyskinesia (TD) Therapy Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

    • 3.1 Global Tardive Dyskinesia (TD) Therapy Sales and Market Share by Manufacturer (2016-2017)
    • 3.2 Global Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Manufacturer (2016-2017)
    • 3.3 Market Concentration Rate
    • 3.3.1 Top 3 Tardive Dyskinesia (TD) Therapy Manufacturer Market Share in 2017
  • 3.3.2 Top 6 Tardive Dyskinesia (TD) Therapy Manufacturer Market Share in 2017
  • 3.4 Market Competition Trend
  • 4 Global Tardive Dyskinesia (TD) Therapy Market Analysis by Regions

    • 4.1 Global Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Regions
    • 4.1.1 Global Tardive Dyskinesia (TD) Therapy Sales and Market Share by Regions (2013-2018)
  • 4.1.2 Global Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Regions (2013-2018)
  • 4.2 North America Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 4.3 Europe Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 4.4 Asia-Pacific Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 4.5 South America Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 4.6 Middle East and Africa Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 5 North America Tardive Dyskinesia (TD) Therapy by Countries

    • 5.1 North America Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Countries
    • 5.1.1 North America Tardive Dyskinesia (TD) Therapy Sales and Market Share by Countries (2013-2018)
  • 5.1.2 North America Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Countries (2013-2018)
  • 5.2 United States Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 5.3 Canada Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 5.4 Mexico Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 6 Europe Tardive Dyskinesia (TD) Therapy by Countries

    • 6.1 Europe Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Countries
    • 6.1.1 Europe Tardive Dyskinesia (TD) Therapy Sales and Market Share by Countries (2013-2018)
  • 6.1.2 Europe Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Countries (2013-2018)
  • 6.2 Germany Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 6.3 UK Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 6.4 France Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 6.5 Russia Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 6.6 Italy Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 7 Asia-Pacific Tardive Dyskinesia (TD) Therapy by Countries

    • 7.1 Asia-Pacific Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Countries
    • 7.1.1 Asia-Pacific Tardive Dyskinesia (TD) Therapy Sales and Market Share by Countries (2013-2018)
  • 7.1.2 Asia-Pacific Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Countries (2013-2018)
  • 7.2 China Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 7.3 Japan Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 7.4 Korea Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 7.5 India Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 7.6 Southeast Asia Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 8 South America Tardive Dyskinesia (TD) Therapy by Countries

    • 8.1 South America Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Countries
    • 8.1.1 South America Tardive Dyskinesia (TD) Therapy Sales and Market Share by Countries (2013-2018)
  • 8.1.2 South America Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Countries (2013-2018)
  • 8.2 Brazil Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 8.3 Argentina Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 8.4 Colombia Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 9 Middle East and Africa Tardive Dyskinesia (TD) Therapy by Countries

    • 9.1 Middle East and Africa Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Countries
    • 9.1.1 Middle East and Africa Tardive Dyskinesia (TD) Therapy Sales and Market Share by Countries (2013-2018)
  • 9.1.2 Middle East and Africa Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Countries (2013-2018)
  • 9.2 Saudi Arabia Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 9.3 UAE Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 9.4 Egypt Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 9.5 Nigeria Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 9.6 South Africa Tardive Dyskinesia (TD) Therapy Sales and Growth Rate (2013-2018)
  • 10 Global Tardive Dyskinesia (TD) Therapy Market Segment by Type

    • 10.1 Global Tardive Dyskinesia (TD) Therapy Sales, Revenue and Market Share by Type (2013-2018)
    • 10.1.1 Global Tardive Dyskinesia (TD) Therapy Sales and Market Share by Type (2013-2018)
  • 10.1.2 Global Tardive Dyskinesia (TD) Therapy Revenue and Market Share by Type (2013-2018)
  • 10.2 Valbenazine Sales Growth and Price
  • 10.2.1 Global Valbenazine Sales Growth (2013-2018)
  • 10.2.2 Global Valbenazine Price (2013-2018)
  • 10.3 Amantadine Sales Growth and Price
  • 10.3.1 Global Amantadine Sales Growth (2013-2018)
  • 10.3.2 Global Amantadine Price (2013-2018)
  • 10.4 Tetrabenazine Sales Growth and Price
  • 10.4.1 Global Tetrabenazine Sales Growth (2013-2018)
  • 10.4.2 Global Tetrabenazine Price (2013-2018)
  • 10.5 Clonazepam Sales Growth and Price
  • 10.5.1 Global Clonazepam Sales Growth (2013-2018)
  • 10.5.2 Global Clonazepam Price (2013-2018)
  • 10.6 Others Sales Growth and Price
  • 10.6.1 Global Others Sales Growth (2013-2018)
  • 10.6.2 Global Others Price (2013-2018)
  • 11 Global Tardive Dyskinesia (TD) Therapy Market Segment by Application

    • 11.1 Global Tardive Dyskinesia (TD) Therapy Sales Market Share by Application (2013-2018)
    • 11.2 Hospitals Sales Growth (2013-2018)
    • 11.3 Clinics Sales Growth (2013-2018)
    • 11.4 Others Sales Growth (2013-2018)

    12 Tardive Dyskinesia (TD) Therapy Market Forecast (2018-2023)

    • 12.1 Global Tardive Dyskinesia (TD) Therapy Sales, Revenue and Growth Rate (2018-2023)
    • 12.2 Tardive Dyskinesia (TD) Therapy Market Forecast by Regions (2018-2023)
    • 12.2.1 North America Tardive Dyskinesia (TD) Therapy Market Forecast (2018-2023)
  • 12.2.2 Europe Tardive Dyskinesia (TD) Therapy Market Forecast (2018-2023)
  • 12.2.3 Asia-Pacific Tardive Dyskinesia (TD) Therapy Market Forecast (2018-2023)
  • 12.2.4 South America Tardive Dyskinesia (TD) Therapy Market Forecast (2018-2023)
  • 12.2.5 Middle East and Africa Tardive Dyskinesia (TD) Therapy Market Forecast (2018-2023)
  • 12.3 Tardive Dyskinesia (TD) Therapy Market Forecast by Type (2018-2023)
  • 12.3.1 Global Tardive Dyskinesia (TD) Therapy Sales Forecast by Type (2018-2023)
  • 12.3.2 Global Tardive Dyskinesia (TD) Therapy Market Share Forecast by Type (2018-2023)
  • 12.4 Tardive Dyskinesia (TD) Therapy Market Forecast by Application (2018-2023)
  • 12.4.1 Global Tardive Dyskinesia (TD) Therapy Sales Forecast by Application (2018-2023)
  • 12.4.2 Global Tardive Dyskinesia (TD) Therapy Market Share Forecast by Application (2018-2023)
  • 13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
    • 13.1.1 Direct Marketing
  • 13.1.2 Indirect Marketing
  • 13.1.3 Marketing Channel Future Trend
  • 13.2 Distributors, Traders and Dealers
  • 14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. 

      Scope of the Report:

      The worldwide market for Tardive Dyskinesia (TD) Therapy is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

      This report focuses on the Tardive Dyskinesia (TD) Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Market Segment by Manufacturers, this report covers

      Teva Pharma

      Biogen

      Johnson & Johnson

      GlaxoSmithKline

      Neurocrine Biosciences

      Pfizer

      Novartis

      Sanofi

      AstraZeneca

      Bayer AG

      Market Segment by Regions, regional analysis covers

      North America (United States, Canada and Mexico)

      Europe (Germany, France, UK, Russia and Italy)

      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

      South America (Brazil, Argentina, Colombia etc.)

      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers

      Valbenazine

      Amantadine

      Tetrabenazine

      Clonazepam

      Others

      Market Segment by Applications, can be divided into

      Hospitals

      Clinics

      Others

      There are 15 Chapters to deeply display the global Tardive Dyskinesia (TD) Therapy market.

      Chapter 1, to describe Tardive Dyskinesia (TD) Therapy Introduction, product scope, market overview, market opportunities, market risk, market driving force;

      Chapter 2, to analyze the top manufacturers of Tardive Dyskinesia (TD) Therapy, with sales, revenue, and price of Tardive Dyskinesia (TD) Therapy, in 2016 and 2017;

      Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

      Chapter 4, to show the global market by regions, with sales, revenue and market share of Tardive Dyskinesia (TD) Therapy, for each region, from 2013 to 2018;

      Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

      Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

      Chapter 12, Tardive Dyskinesia (TD) Therapy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

      Chapter 13, 14 and 15, to describe Tardive Dyskinesia (TD) Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source




      Summary:
      Get latest Market Research Reports on Tardive Dyskinesia (TD) Therapy . Industry analysis & Market Report on Tardive Dyskinesia (TD) Therapy is a syndicated market report, published as Global Tardive Dyskinesia (TD) Therapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Tardive Dyskinesia (TD) Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,336.82
      3,505.23
      4,673.64
      3,202.30
      4,803.44
      6,404.59
      421,567.20
      632,350.80
      843,134.40
      230,770.63
      346,155.95
      461,541.26
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report